: iStockAnalyst.com Symbols Feed

Transgenomic Finds China Partner

Mon, 07 Apr 2008 18:48:56 GMT

Transgenomic, Inc. (OTCBB: TBIO) announced a new laboratory services partnership with the Guangzhou Family...[More...]

Currency Swings Hit Transgenomic's Bottom Line

Sat, 16 May 2009 09:48:00 GMT

May 16--The impact of foreign currency fluctuations tied to the worldwide recession weighed heavily on Transgenomic Inc. in the first quarter.
Revenue at the Omaha biotechnology company dropped by $1.27 million, about 20 percent.
In just one category of sales, consumable supplies, revenue dropped by $432,000 from the first quarter of 2008 to $1.8 million, Chief Financial Officer Debra Schneider said on a conference call Thursday.

[More...]

Omaha World-Herald, Neb., World-Herald Staff Writer Column: Earnings: EFJohnson Technologies

Sun, 02 Nov 2008 07:48:00 GMT

Nov. 2--Third quarter: Profits were $422,000, a sharp reversal from the $3.4 million loss in the third quarter of 2007.
Results for the first nine months: $678,000 loss, 3 cents a share, compared with profits of $113,000 in 2007 on revenue that dropped to $101 million from $130 million.
Quarterly highlights: The Irving, Texas, company, which has operations in Lincoln, reported several contracts for sale of the two-way radio equipment and encryption technologies to defense and public safety agencies.

[More...]

Transgenomic, Inc. Reports Second Quarter 2009 Results

Wed, 12 Aug 2009 19:55:00 GMT

Transgenomic, Inc. today announced financial results for the quarter ended June 30, 2009. The Company's financial results are presented in the tables that follow.[More...]

Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast

Wed, 12 Aug 2009 13:43:00 GMT

Transgenomic Inc. announces the following Webcast:[More...]

Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast

Thu, 06 Aug 2009 15:14:00 GMT

Transgenomic Inc. announces the following Webcast:[More...]

Transgenomic, Inc. Announces Appointment of New Board Members

Fri, 22 May 2009 21:42:00 GMT

Transgenomic, Inc. announces that it has appointed Antonius P. Schuh, Ph.D. and Michael B. McNulty to its Board of Directors.[More...]

Transgenomic, Inc. Reports First Quarter 2009 Results

Wed, 13 May 2009 19:55:00 GMT

Transgenomic, Inc. today announced financial results for the first quarter ended March 31, 2009. The Company's financial results are presented in the tables that follow.[More...]

Reminder: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast

Wed, 13 May 2009 11:55:00 GMT

Transgenomic Inc. announces the following Webcast:[More...]

Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting

Mon, 11 May 2009 15:44:00 GMT

Collaboration with Noted Neurologists to Plan Next Clinical Studies[More...]

Webcast Alert: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast

Thu, 07 May 2009 18:51:00 GMT

Transgenomic Inc. announces the following Webcast:[More...]

Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations

Tue, 07 Apr 2009 16:01:00 GMT

Transgenomic, Inc. , a leading global biotechnology company, announces that it has completed a licensing option with the Dana-Farber Cancer Institute, Boston, MA with regard to a method known as Cold-PCR. This variation of the standard PCR technology enriches mutations in samples where normal DNA predominates. Cold-PCR was invented at Dana-Farber by Dr. Mike Makrigiorgos who has demonstrated its effectiveness in enriching for mutations in cancer-related genes in samples where DNA sequencing cannot detect very low concentrations of somatic DNA mutation.[More...]

Polycystic Kidney Disease Assay at Cornell University Uses Transgenomic's Surveyor Nuclease & WAVE Technology

Thu, 02 Apr 2009 20:57:00 GMT

Transgenomic, Inc. . In a peer-reviewed paper published in the February 2009 issue of the journal Human Mutation, a team at Weill Cornell Medical College New York describes in detail the key advantages of using Transgenomic's Surveyor Nuclease technology for mutation scanning of PKD1 and PKD2, two important genes used in the diagnosis and prognosis of autosomal dominant polycystic kidney disease . The assay showed 100% concordance with the current standard, DNA sequencing, but decreased sequencing requirements by 80%, significantly reducing analysis time and cost.[More...]